New hope for leukemia patients: targeted therapy aims to eliminate hidden cancer cells

NCT ID NCT03737955

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a targeted drug called gemtuzumab ozogamicin can clear tiny amounts of leukemia that remain after initial treatment in adults with acute myeloid leukemia (AML). The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a chemotherapy payload directly to them. About 36 participants will receive the drug in divided doses, and researchers will check if it can eliminate these leftover cancer cells without causing severe side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute monocytic leukemia acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutchinson Cancer Center/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact